Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

  • ID: 3845368
  • Drug Pipelines
  • 38 pages
  • Global Markets Direct
1 of 6
Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016

Summary

‘Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H2 2016’, provides an overview of the Proliferative Vitreoretinopathy (PVR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR)
- The report reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects
- The report assesses Proliferative Vitreoretinopathy (PVR) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Proliferative Vitreoretinopathy (PVR)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Proliferative Vitreoretinopathy (PVR) Overview

Therapeutics Development

Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Overview

Pipeline Products for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis

Proliferative Vitreoretinopathy (PVR) - Therapeutics under Development by Companies

Proliferative Vitreoretinopathy (PVR) - Therapeutics under Investigation by Universities/Institutes

Proliferative Vitreoretinopathy (PVR) - Pipeline Products Glance

Early Stage Products

Proliferative Vitreoretinopathy (PVR) - Products under Development by Companies

Proliferative Vitreoretinopathy (PVR) - Products under Investigation by Universities/Institutes

Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development

Novartis AG

Promedior, Inc.

RXi Pharmaceuticals Corporation

Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LD-224 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRM-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XOMA-089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proliferative Vitreoretinopathy (PVR) - Dormant Projects

Proliferative Vitreoretinopathy (PVR) - Product Development Milestones

Featured News & Press Releases

Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences

May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform

May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting

May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016

Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H2 2016

Proliferative Vitreoretinopathy (PVR) - Pipeline by Promedior, Inc., H2 2016

Proliferative Vitreoretinopathy (PVR) - Pipeline by RXi Pharmaceuticals Corporation, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H2 2016 32List of Figures

Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H2 2016

Number of Products under Development for Proliferative Vitreoretinopathy (PVR) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Proliferative Vitreoretinopathy (PVR) pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proliferative Vitreoretinopathy (PVR) Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes. The molecules developed by Companies in Preclinical and Discovery stages are 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Novartis AG
Promedior, Inc.
RXi Pharmaceuticals Corporation
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll